[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352230-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352230-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-a-two-gene-biomarker-correlated-with-sensitivity-to-combined-parp7-inhibition-and-ahr-activation-in-cancer-cells","Identification of a Two-Gene Biomarker - Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells","","PARP7 inhibitors (PARP7i) and aryl hydrocarbon receptor agonists (AHRa) can synergistically suppress growth in subsets of cancer cell lines. The study constructs a two-gene transcriptional score to predict synergistic response and characterizes its molecular, immune, and prognostic properties. Using published RNA-seq data, it defines the biomarker from CCL22 and TNFSF10 and validates it in an independent cell-line set. Multiomics and network analyses link synergy to immune gene expression, reduced epithelial–mesenchymal transition signatures, transcription factors, and immune infiltration correlations in TCGA breast and prostate cancers. The biomarker also associates with response to anti–PD-1 therapy and improved survival under anti–PD-L1 and anti–CTLA-4 treatments.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-a-two-gene-biomarker-correlated-with-sensitivity-to-combined-parp7-inhibition-and-ahr-activation-in-cancer-cells/352230/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-a-two-gene-biomarker-correlated-with-sensitivity-to-combined-parp7-inhibition-and-ahr-activation-in-cancer-cells/352230.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main aim of this study?","Question",{"text":63,"@type":64},"To identify and validate a two-gene transcriptional biomarker that predicts cellular sensitivity to combined PARP7 inhibition and AHR activation in cancer cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the two-gene biomarker constructed and validated?",{"text":68,"@type":64},"Published RNA sequencing data were used to define a biomarker based on the expression of two immune-related genes, CCL22 and TNFSF10, and it was validated in an independent set of cell lines.",{"name":70,"@type":61,"acceptedAnswer":71},"What biological and clinical associations are reported for the biomarker?",{"text":72,"@type":64},"Synergistic lines show increased immune-related gene sets and lower epithelial–mesenchymal transition–associated gene expression; in TCGA breast and prostate cancers, biomarker genes correlate with immune cell infiltration, and biomarker scores link to response to anti–PD-1 and improved outcomes with anti–PD-L1 and anti–CTLA-4 therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352230,1790222839,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0173](https://doi.org/10.1158/2767-9764.CRC-25-0173)  OPEN ACCESS  \nIdentification of a Two-Gene Biomarker   \nCorrelated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells  \nXuxu Gou, Huadong Chen, Morgan E. Diolaiti, and Alan Ashworth  \n􀀶  \nABSTRACT  \nPARP7 inhibitors (PARP7i) and aryl hydrocarbon receptor agonists (AHRa) can synergistically suppress growth of some cancer cell lines but not others. In this study, we derived a two-gene transcriptional score to predict the synergistic response and characterized the molecular, immune, and prognostic features of this biomarker. Cancer cells were categorized into synergistic and nonsynergistic cell lines based on synergy scores that we previously reported. Published RNA sequencing data were used to establish a biomarker for PARP7i and AHRa synergistic response that was comprised of the expression of the two most differentially expressed immune-related genes (CCL22 and TNFSF10) . This biomarker was successfully validated in an independent set of cell lines. An integrated multiomics analysis revealed that synergistic lines had increased expression of immune-related gene sets and low expression of epithelial–mesenchymal transition–associated genes and co-expression network analysis identified transcription factors associated with synergy. In The Cancer Genome Atlas patients with breast and prostate cancers, biomarker genes were correlated with immune cell infiltration. Receiver  \noperator characteristic (ROC) and hazard ratio (HR) analyses demonstrated that the biomarker score was correlated with response to anti– programmed cell death protein 1 (PD-1) therapy in a cohort of patients with kidney cancer and correlated with better overall survival in patients with cancer treated with anti–programmed cell death ligand 1 (PD-L1) and anti–cytotoxic T-lymphocyte–associated protein 4 therapies. In summary, we have identified a transcriptional biomarker that predicts cellular response to PARP7i and AHRa combination therapy, which is associated with benefits from immune checkpoint inhibitor therapies inpatients with cancer.  \nSignificance: We employed a multiomic approach to identify a transcriptional biomarker that is predictive of cellular response to combined treatment with PARP7i and AHRa. The molecular, immune, and prognostic characterizations of this biomarker may provide insights into the molecular mechanisms of response and aid in stratifying patients likely to benefit from this combination therapy.  \nIntroduction  \nPoly (ADP-ribose) polymerase 7 (TIPARP/PARP7) is a member of the PARP family of enzymes known for their role in regulating immune response ( 1–3) . Mechanistically, PARP7 catalyzes the transfer of a single ADP-ribose (ADPr) from NAD+ to protein targets, a process known as mono-ADPribosylation (MARylation; ref. 4) . Unlike PARP1, which is primarily involved in DNA damage repair, PARP7 is a key regulator of immune signaling ( 1, 5). Although the pathways affected by PARP7 have not been fully  \nHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.  \nCorresponding Author: Alan Ashworth, UCSF Helen Diller Family Comprehensive Cancer Center, 1450 3rd Street, Room HD-271, Box 0128, San Francisco, CA 94158. [E-mail:](E-mail: Alan.Ashworth@ucsf.edu)[ Alan.Ashworth@ucsf.edu](E-mail: Alan.Ashworth@ucsf.edu)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-25-0173  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2025 The Authors; Published by the American Association for Cancer Research  \nelucidated, PARP7 has been shown to repress type I interferon (IFN) response by MARylating TBK1 and downstream targets ( 1, 5) . This modification disrupts the ability of TBK1 to activate downstream signaling cascades, including the phosphorylat","cbCailj7T1QQjEKJ","https://ap.wps.com/l/cbCailj7T1QQjEKJ","pdf",3986869,12,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What is the main aim of this study?\",\"answer\":\"To identify and validate a two-gene transcriptional biomarker that predicts cellular sensitivity to combined PARP7 inhibition and AHR activation in cancer cells.\"},{\"question\":\"How is the two-gene biomarker constructed and validated?\",\"answer\":\"Published RNA sequencing data were used to define a biomarker based on the expression of two immune-related genes, CCL22 and TNFSF10, and it was validated in an independent set of cell lines.\"},{\"question\":\"What biological and clinical associations are reported for the biomarker?\",\"answer\":\"Synergistic lines show increased immune-related gene sets and lower epithelial–mesenchymal transition–associated gene expression; in TCGA breast and prostate cancers, biomarker genes correlate with immune cell infiltration, and biomarker scores link to response to anti–PD-1 and improved outcomes with anti–PD-L1 and anti–CTLA-4 therapies.\"}]","Identification of a Two-Gene Biomarker - Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells | PDF",1790098434,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4fc2bbb95b926bbc155685210f8decc3.webp",983,1263,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5812a6cab16d249320b44bcf529e71c9.webp",982,1262,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b15816c791bcde6d9c8653c174ffb1fc.webp",981,1261,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd664a291b32525b65f085028b87dbcb.webp",980,1259]